Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma

MLA

Maruki, Taketomo, et al. “Successful Management of Persistent COVID-19 Using Combination Antiviral Therapy (Nirmatrelvir/Ritonavir and Remdesivir) and Intravenous Immunoglobulin Transfusion in an Immunocompromised Host Who Had Received CD20 Depleting Therapy for Follicular Lymphoma.” Journal of Infection & Chemotherapy (Elsevier Inc.), vol. 30, no. 8, Aug. 2024, pp. 793–95. EBSCOhost, https://doi.org/10.1016/j.jiac.2024.01.008.

APA

Maruki, T., Nomoto, H., Iwamoto, N., Yamamoto, K., Kurokawa, M., Iwatsuki-Horimoto, K., Yamayoshi, S., Suzuki, Y., Kawaoka, Y., & Ohmagari, N. (2024). Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma. Journal of Infection & Chemotherapy (Elsevier Inc.), 30(8), 793–795. https://doi.org/10.1016/j.jiac.2024.01.008

Chicago

Maruki, Taketomo, Hidetoshi Nomoto, Noriko Iwamoto, Kei Yamamoto, Masami Kurokawa, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Yutaka Suzuki, Yoshihiro Kawaoka, and Norio Ohmagari. 2024. “Successful Management of Persistent COVID-19 Using Combination Antiviral Therapy (Nirmatrelvir/Ritonavir and Remdesivir) and Intravenous Immunoglobulin Transfusion in an Immunocompromised Host Who Had Received CD20 Depleting Therapy for Follicular Lymphoma.” Journal of Infection & Chemotherapy (Elsevier Inc.) 30 (8): 793–95. doi:10.1016/j.jiac.2024.01.008.